-
Cambodian PM's cousin says owned 30% of scam-linked firm
-
Hegseth's church brings its Christian nationalism to Washington
-
Afrobeats' Tiwa Savage nurtures Africa's future talent
-
Venice Biennale opens in turmoil over Russian presence
-
Philips profits double in first quarter
-
Strasbourg on verge of European final amid fan displeasure at owners BlueCo
-
Tradition, Trump and tennis: Five things about Pope Leo
-
100 years on Earth: Iconic naturalist Attenborough marks century
-
Bondi Beach mass shooting accused faces 19 extra charges
-
Ukraine reports strike as Kyiv's ceasefire due to begin
-
Australia says 13 citizens linked to alleged IS members returning from Syria
-
Thunder overpower Lakers, Pistons down Cavs
-
Boycott-hit 70th Eurovision celebrated under high security
-
Court case challenges New Zealand's 'magical thinking' climate plans
-
Iran war jolts China's well-oiled manufacturing hub
-
Oil sinks and stocks rally on peace hopes, Samsung tops $1 trillion
-
Infantino defends World Cup ticket prices
-
Pistons hold off Cavs to win series-opener
-
Rubio rising? Duel with Vance for 2028 heats up
-
Teen shooter kills two at Brazil school
-
US pauses Hormuz escorts in bid for deal, as threats continue
-
Judge orders German car-ramming suspect to psychiatric hospital
-
Fresh UAE attacks blamed on Iran draw new reality in the Gulf
-
Transoft Solutions Acquires CADaptor Solutions
-
Arsenal on cusp of history after reaching Champions League final
-
Trump says pausing Hormuz operation in push for Iran deal
-
Wembanyama accused of 'obvious' illegal blocking
-
Musk 'was going to hit me,' OpenAI executive says at trial
-
NFL star Diggs cleared of assaulting personal chef
-
Fans 'set the standards' at rocking Emirates: Arteta
-
Rubio warns against 'destabilizing' acts on Taiwan before Trump China visit
-
US declares Iran offensive over, warns force remains an option
-
Saka ends Arsenal's 20-year wait to reach Champions League final
-
Outgoing Costa Rica leader secures top post in new cabinet
-
Rubio plays down Trump attacks on pope before Vatican trip
-
LIV Golf boss sees hope for new sponsors beyond 2026
-
Mexican BTS fans go wild as concerts grow near
-
Europe's first commercial robotaxi service rolls out in Croatia
-
Russian strikes kill 21 in Ukraine
-
Suspected hantavirus cases to be evacuated from cruise ship
-
G7 trade ministers meet, not expected to discuss US tariff threat
-
Hollywood star Malkovich gets Croatian citizenship
-
Mickelson pulls out of PGA Championship for family issues
-
Wales rugby great Halfpenny to retire
-
Rahm says player concessions needed to save LIV Golf
-
Bowlers, Samson keep Chennai afloat in IPL playoff race
-
Rolling Stones announce July 10 release of new album 'Foreign Tongues'
-
France's Macron taps ex-aide to head central bank
-
PSG 'not here to defend' against Bayern, says Luis Enrique
-
Trump says he works out 'one minute a day' as he restores fitness award
US FDA says Pfizer Covid vaccine effective in kids under five
The US Food and Drug Administration (FDA) has said the Pfizer Covid vaccine is safe and effective in children under five, ahead of a meeting to weigh its authorization later this week.
Children under five are the only age group not yet eligible for vaccination in the United States and most countries, a pressing need since rates of hospitalization and death "are higher than among children and adolescents 5-17 years of age," the FDA said in a document posted on its website Sunday.
The agency has called a meeting of experts on June 15 to decide whether to recommend the Pfizer vaccine, given as three shots to children aged six months through four years, as well as the Moderna vaccine, given as two shots to children aged six months through five years.
Pfizer's first two shots are given three weeks apart, then the third is given eight weeks after the second. They are all dosed at three micrograms, as opposed to 30 micrograms the company gives older ages.
Both Pfizer and Moderna had previously posted their results, but the FDA then had to review the data in detail and carry out its own evaluation. It posted a favorable analysis about Moderna on Friday.
Its comments towards Pfizer also appear favorable, based on the levels of infection-blocking antibodies it evoked in trial participants, and a similar side-effect profile to higher age groups. The trial population was around 4,500 children.
A preliminary estimate placed vaccine efficacy at 80.3 percent, but the FDA noted this was based on very few positive cases -- just 10, as opposed to the 21 sought for a more accurate figure.
There are nearly 20 million US children aged four years and under, or six percent of the population. If, as expected, the FDA-appointed experts recommend the two shots, then the matter will go to another committee convened by the Centers for Disease Control and Prevention for a final say.
White House officials last week said rollout of millions of shots at pharmacies and doctors' offices could begin as soon as June 21, following the Juneteenth holiday on June 20.
P.L.Madureira--PC